

Thyroid Uptake & Nodule ablation

Mohammad Abuqbeitah


PhD candidate

Istanbul University-Cerrahpaşa

Nuclear Medicine Dept.



- ▶ **Thyroid gland** secretes three hormones, namely (thyroxine/ T_4 and triiodothyronine/ T_3), and calcitonin.
- ▶ **TG** controls many parts of human's metabolism, (heart beats and burning calories).
- ▶ **TSH** is released by the anterior pituitary and stimulates the thyroid follicular cells to release thyroxine, T_4 (80%) and triiodothyronine, or T_3 (20%)



Thyroid diseases

Hyper-thyroidism

- ▶ when it makes too many hormones.
 - ▶ 1- Graves
 - ▶ 2- Toxic Adenoma
- Overactive nodule in the thyroid

Hypo-thyroidism

- ▶ when the gland doesn't make enough hormones.
- ▶ Causes: insufficient iodine, thyroiditis, radiation exposure

....Thyroid cancer

Benign Cancer

- ▶ Greaves
- ▶ Toxic adenoma



Malignant Cancer

- ▶ Well-Differentiated group
 - ❖ Papillary adencarcinoma
 - ❖ Follicular
 - ❖ H- cell cancer
- Medullary
- Anaplastic Cancer


Thyroid Diseases Treatment

- ▶ **Medication:** Thyroiditis
- ▶ **Surgery:** Goiter, hyperthyroidism and cancer
- ▶ **Radiation therapy:** Medullary and anaplastic cancers
- ▶ **Radiofrequency:** Nodular thyroid
- ▶ **Radioactive 131I:** benign cancer and post-thyroidectomy


Toxic adenoma



Thyroid Residues (Post-thyroidectomy)




Nodular Therapy



Radiofrequency

- ▶ RF ablation uses the **heat** generated from high-frequency alternating electric current oscillating between **200 and 1200 kHz**.
- ▶ RF power is **30–120 W** depending on the **size of the active tip** and the internal characteristics of the nodules
- ▶ **Active tips** of various lengths, for example, **0.5, 0.7, 1.0, or 1.5 cm**
- ▶ The RF waves passing through the electrode agitate tissue ions around the electrode, and they increase the temperature (by **frictional heat**) within the tumour tissue.
- ▶ At temperatures between **60 and 100°C**, nearly immediate tissue coagulation is induced with **irreversible damage** caused to tumour tissue,
- ▶ while temperatures greater than **100–110°C** result in tissue vaporization and carbonization.
- ▶ **Ground pads** (dispersive electrodes) applied to the skin are connected to the radiofrequency generator, and the generator is connected to the RF needle electrode







Set Continuance Mode
1cm active tip
Target RF power: 50 watt





MONOPOLAR RFA

ground pads are placed
 at both patient's thighs
 in order to create a
 closed-loop circuit

Moving shot technique





Radioiodine (^{131}I) therapy

Table 1. Physical properties of iodine-131 [2]

Type of radiation emitted	Energy	Percentage
Beta minus (electrons)	248 keV	2.1
	334 keV	7.4
	606 keV	89.3
	812 keV	0.7
	723 keV	1.8
Gamma	637 keV	7.3
	364 keV	81.2
	284 keV	6.1
	80 keV	2.6






Figure 1. Atom ionization by the electron β^-

Figure 3. Penetration of the electron β^- in the thyroid [5]




^{131}I treatment routes

► Fixed dose (empirical):-

- Toxic Adenoma: Administer 7.4 GBq (200 mCi) depending on the 2 and 24 hours uptake
- Thyroid Cancer: Administer 3.7 GBq (100 mCi) depending on the 2 and 24 hours uptake


► Dosimetry based

- ❑ Patient specific: Administer 1.1 GBq (30 mCi) if the iodine biokinetic study shows adequate uptake
- ❑ Absorbed dose: Administer 1.1 GBq (30 mCi) if the patient is not as toxic




Thyroid Dosimetry Headlines...

- ▶ Tracer administration: 10-20 μCi ^{131}I for TA, 100-200 μCi for Thyroid ablation
- ▶ Deriving *time –Activity Curve* by acquiring subsequent uptake values along 96-168 hours.
- ▶ *Cumulative Activity* calculation
- ▶ *Dose* calculation
- ▶ Estimating the **activity** that will deliver desired dose e.g 300 Gy



Clinical Study




Inclusion Criteria

- ▶ Our study comprised patients of **Greaves** (n=18), and Toxic Adenoma (n=10)

<u>Test</u>	<u>FT3 (pg/ml)</u>	<u>FT4 (ng/dl)</u>	<u>TSH (μIU/mL)</u>
Reference values	2-4.4	0.93-1.7	0.27-4.2

- ▶ A Properly calibrated **thyroid uptake probe** with NaI(Tl) was employed to acquire uptake measures.
- ▶ Energy photopeak was set as 364 Kev with 20% window width
- ▶ **U.S** was used for **volume** determination
- ▶ $V = 4/3 \times (xyz/2)^3 \times \pi$



Nodule Uptake

- $(RIU) \% = \frac{Nc - Fc}{Sc - BG} \times 100$

Nc: Neck counts

Fc: Femure counts

BG: background counts




Conversion Factor

To convert the counts into Activity as c/MBq .



✓ Absorbed Dose Calculation

1- MIRD method



Doses from Nuclide: I-131 in Spheres:

Sphere Mass (g)	Dose (mGy/MBq)
0.01	3,87E004
0.1	4,18E003
0.5	8,55E002
1.0	4,45E002
2.0	2,25E002
4.0	1,14E002
6.0	7,69E001
8.0	5,79E001
10.0	4,67E001
20.0	2,38E001
40.0	1,21E001
60.0	8,19E000
80.0	6,22E000
100.0	5,03E000



► $Dose = \bar{A} \times S$

$mass = V \times D$

2- Time effective based model

$$A = \frac{0.714}{\bar{E}} \times \frac{M \cdot D}{RIU_{(t_1)} \cdot 2^{(t_1/T_{eff})} \cdot T_{(eff)}}$$

$$T_{eff} = \frac{(t_1 - t_{max}) \cdot \ln(2)}{\ln RIU_{max} - \ln RIU_{t_1}}$$

Hänscheid et al. (2013)

3- The ellipsoidal thyroid

$$A = \frac{D \cdot M}{RIU_{max} \cdot T_{eff}} \cdot \frac{32.31\rho + 1}{\rho(0.2625\rho + 5.1819)}$$

$$\rho = \frac{3v}{s}$$

$$V = \frac{4}{3} \cdot abc \cdot \pi, \quad S = 4\pi \left(\frac{(ab)^p (bc)^p (ac)^p}{3} \right)^{1/p}$$

Amato et al. (2011)



Findings....


Physical parameters following ^{131}I tracer

Parameter	Graves (n=15)	Toxic adenoma (n=10)
Thyroid volume ($\text{m}\pm\text{sd}$ cm^3)	22 ± 10	45 ± 36
Effective half life ($\text{m}\pm\text{sd}$ h)	128 ± 40	95 ± 43
Residence time ($\text{m}\pm\text{sd}$ h)	116 ± 45	106 ± 63




Teff and Ellipsoid Deviation to MIRD for GRAVES patients

Method	Min %	Mean %	Max %	P _{value}
Teff	-14	-3	20	0.74
Ellipsoid	1	15	28	0.76



Teff and Ellipsoid Deviation to Unite density model for *TOXIC ADENOMA* Patients

Method	Min %	Mean %	Max %	P _{value}
Teff	1.2	41	94	0.09
Ellipsoid	6.5	65	194	0.03



Clinical outcome

Toxic Adenoma

- ▶ 100% of the patients showed **Authyroid** status after receiving **360±66 Gy**.

Graves

- ▶ 13 patients received **240±55 Gy** following dosimetry showed **authyroid or minimum hypothyroidism** during 3-6 months.
- ▶ 5 patients who were empirically treated recieved **≥ 385 Gy** and portrated **HYPOTHYROIDISM**

No patient underwent further dose during 2 years



Before therapy



TSH 0.005 **FT3** 32.55 **FT4** 7.24

Max/Min uptake	86/57%
Nodule vol (cm³)	163

E.H.T(h)	122
-----------------	-----

Rt (h)	243
---------------	-----

A₀ (MBq)	1591
----------------------------	------

AD (Gy)	300
----------------	-----

6 months after therapy



✓ **Normal** hormone levels
TSH(0.27)/FT3(3.3)/FT4:(1.59)

✓ **Authyroid** status

✓ **98%** nodule shrinkage



To this end...

- ▶ **Evidence based therapy** is more realistic and effective in retring AUTHYROID status in RIT of benign cancer.
- ▶ empirical regime lacks the **turn over phase** that justify the common failure in restoring authyroid status.
- ▶ The formula with 3 uptake **measures** and **effective half life** seems **appropriate and cost effective** in the daily practice .
- ▶ Unit density sphere model is **pretty successive** in Toxic Adenoma with **250-300 GY**
- ▶ The ellipsoidal shape of the thyroid or nodule is **irrelevant** in the dosimetry of benign cancer owing to the obtained clinical outcomes.

Thank you



Doğuş
kilisesi

- ❑ Doğuş Kilisesi, Filistin'de Batı Şeria'daki Beytüllahim'de bulunan bir bazilikadır.
- ❑ Kilise ilk olarak 327 yılında I. Konstantin ve annesi Helena tarafından, İsa'nın doğum yerini olarak bilinen mağaranın üzerine inşa edildi



Hız.İsa'nın doğum yeri